Analysis of Driver Gene Mutation in Early Stage Non-small Cell Lung Cancer

NCT ID: NCT04266691

Last Updated: 2020-02-12

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 237 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2009-01-31
• Study Completion Date: 2019-06-30

Brief Summary

Analysis of driver gene variation in early stage non-small cell lung cancer

Detailed Description

Fluorescence quantitative polymerase chain reaction (PCR) was used to detect the variation of driver gene in regional lymph nodes of early stage non-small cell lung cancer (NSCLC), and to analyze the relationship between the variation and disease recurrence and survival prognosis. evaluate the effect of the variation of driving gene in lymph nodes of early stage NSCLC on prognosis, identify the high-risk factors that promote the recurrence and metastasis of early stage tumor. so as to improve the diagnosis and treatment path of lung cancer, provide important pathological basis for the clinical diagnosis and treatment of early stage non-small cell lung cancer, enable patients to receive more accurate treatment, and improve their survival prognosis.

Conditions

Non-small Cell Lung Cancer

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Driver gene mutation-positive

Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation positive.

nonIntervention

Intervention Type: OTHER

nonIntervention

Driver gene mutation-negative

Screen the enrolled patients according to the admission criteria. The detection of lung cancer Polymerase Chain Reaction (PCR) panel kit in the hospital requires the use of tissue samples and the results show a driver gene mutation negative.

nonIntervention

Intervention Type: OTHER

nonIntervention

Interventions

nonIntervention

nonIntervention

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Female or male, 18 years of age or older

2. Histologically or cytologically proven diagnosis of early stage NSCLC

3. The lesion was completely resected by radical surgery

4. Able to get tumor tissue sample

5. Complete information of clinicopathological , survival, recurrence and metastasis can be obtained through follow-up

Exclusion Criteria

1. Combine with other tumor type

2. The investigator judges the situation that may affect the clinical search process and results

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Zhejiang Cancer Hospital

OTHER

Sponsor Role: lead

Responsible Party

zjszlyyad@126.com

Director of pathology

Responsibility Role: PRINCIPAL_INVESTIGATOR

References

Tian Y, Lai Q, Zheng Y, Ying L, Wang C, Jin J, Huang M, Wu Y, Li H, Zhang J, Su D. Oncogenic Alterations in Histologically Negative Lymph Nodes Are Associated with Prognosis of Patients with Stage I Lung Adenocarcinoma. Cancers (Basel). 2022 Feb 6;14(3):824. doi: 10.3390/cancers14030824.

Reference Type: DERIVED

PMID: 35159091 (View on PubMed)

Other Identifiers

LN-OMs

Identifier Type: -

Identifier Source: org_study_id